Long Ideas - Shares of BioMarin Pharmaceuticals (NASDAQ:BMRN) have risen roughly 40% in 2012, driven by solid Phase III data for BMRN’s lead investigational product GALNS, a treatment … Continue Reading
Read nowLong Ideas - Raptor Pharmaceutical (NASDAQ:RPTP) is developing treatments for rare diseases and has a compelling pipeline positioned to take advantage of unmet medical needs. The company has … Continue Reading
Read nowLong Ideas - Shares of ViroPharma (NASDAQ:VPHM) have been pressured in 2012 (falling over 17% as of December 26), as generic competition for one of its drugs has … Continue Reading
Read now- Few investors that choose to invest in the biotechnology sector expect stability. Biotechnology stocks may be insulated from macroeconomic issues, but they are exposed to … Continue Reading
Read nowLong Ideas - For biotechnology investors, a biotechnology company’s “pivot” period, the time frame when it transitions from a development-stage company to a solidly profitable company can often … Continue Reading
Read nowLong Ideas - The war against cancer has proven to be a difficult war to win. For decades, researchers and doctors have looked for ways to more effectively … Continue Reading
Read nowMost Popular - Many investors who choose to invest in the sector choose, for better to worse, to focus only on the clinical and medicinal aspects of these … Continue Reading
Read now